107 related articles for article (PubMed ID: 29769710)
21. Adiponectin determines farnesoid X receptor agonism-mediated cardioprotection against post-infarction remodelling and dysfunction.
Xia Y; Zhang F; Zhao S; Li Y; Chen X; Gao E; Xu X; Xiong Z; Zhang X; Zhang J; Zhao H; Wang W; Wang H; Guo Y; Liu Y; Li C; Wang S; Zhang L; Yan W; Tao L
Cardiovasc Res; 2018 Aug; 114(10):1335-1349. PubMed ID: 29668847
[TBL] [Abstract][Full Text] [Related]
22. Syndecan-4 deficiency accelerates the transition from compensated hypertrophy to heart failure following pressure overload.
Li G; Xie J; Chen J; Li R; Wu H; Zhang X; Chen Q; Gu R; Xu B
Cardiovasc Pathol; 2017; 28():74-79. PubMed ID: 28395201
[TBL] [Abstract][Full Text] [Related]
23. Adiponectin protects against the development of systolic dysfunction following myocardial infarction.
Shibata R; Izumiya Y; Sato K; Papanicolaou K; Kihara S; Colucci WS; Sam F; Ouchi N; Walsh K
J Mol Cell Cardiol; 2007 Jun; 42(6):1065-74. PubMed ID: 17499764
[TBL] [Abstract][Full Text] [Related]
24. In vivo and in vitro protective effects of pentamethylquercetin on cardiac hypertrophy.
He T; Chen L; Chen Y; Han Y; Yang WQ; Jin MW
Cardiovasc Drugs Ther; 2012 Apr; 26(2):109-20. PubMed ID: 22183794
[TBL] [Abstract][Full Text] [Related]
25. Overexpression of prostaglandin E2 EP4 receptor improves cardiac function after myocardial infarction.
Bryson TD; Gu X; Khalil RM; Khan S; Zhu L; Xu J; Peterson E; Yang XP; Harding P
J Mol Cell Cardiol; 2018 May; 118():1-12. PubMed ID: 29522761
[TBL] [Abstract][Full Text] [Related]
26. Overexpression of A kinase interacting protein 1 attenuates myocardial ischaemia/reperfusion injury but does not influence heart failure development.
Booij HG; Yu H; De Boer RA; van de Kolk CW; van de Sluis B; Van Deursen JM; Van Gilst WH; Silljé HH; Westenbrink BD
Cardiovasc Res; 2016 Aug; 111(3):217-26. PubMed ID: 27302402
[TBL] [Abstract][Full Text] [Related]
27. Cardiomyocyte-specific transgenic expression of lysyl oxidase-like protein-1 induces cardiac hypertrophy in mice.
Ohmura H; Yasukawa H; Minami T; Sugi Y; Oba T; Nagata T; Kyogoku S; Ohshima H; Aoki H; Imaizumi T
Hypertens Res; 2012 Nov; 35(11):1063-8. PubMed ID: 22763477
[TBL] [Abstract][Full Text] [Related]
28. Celiprolol, a vasodilatory beta-blocker, inhibits pressure overload-induced cardiac hypertrophy and prevents the transition to heart failure via nitric oxide-dependent mechanisms in mice.
Liao Y; Asakura M; Takashima S; Ogai A; Asano Y; Shintani Y; Minamino T; Asanuma H; Sanada S; Kim J; Kitamura S; Tomoike H; Hori M; Kitakaze M
Circulation; 2004 Aug; 110(6):692-9. PubMed ID: 15262839
[TBL] [Abstract][Full Text] [Related]
29. Cardiomyocyte-specific overexpression of nitric oxide synthase 3 improves left ventricular performance and reduces compensatory hypertrophy after myocardial infarction.
Janssens S; Pokreisz P; Schoonjans L; Pellens M; Vermeersch P; Tjwa M; Jans P; Scherrer-Crosbie M; Picard MH; Szelid Z; Gillijns H; Van de Werf F; Collen D; Bloch KD
Circ Res; 2004 May; 94(9):1256-62. PubMed ID: 15044322
[TBL] [Abstract][Full Text] [Related]
30. Plasminogen Activator Inhibitor Type I Controls Cardiomyocyte Transforming Growth Factor-β and Cardiac Fibrosis.
Flevaris P; Khan SS; Eren M; Schuldt AJT; Shah SJ; Lee DC; Gupta S; Shapiro AD; Burridge PW; Ghosh AK; Vaughan DE
Circulation; 2017 Aug; 136(7):664-679. PubMed ID: 28588076
[TBL] [Abstract][Full Text] [Related]
31. Antiandrogenic therapy with finasteride attenuates cardiac hypertrophy and left ventricular dysfunction.
Zwadlo C; Schmidtmann E; Szaroszyk M; Kattih B; Froese N; Hinz H; Schmitto JD; Widder J; Batkai S; Bähre H; Kaever V; Thum T; Bauersachs J; Heineke J
Circulation; 2015 Mar; 131(12):1071-81. PubMed ID: 25632043
[TBL] [Abstract][Full Text] [Related]
32. Increased fibrosis and progression to heart failure in MRL mice following ischemia/reperfusion injury.
Smiley D; Smith MA; Carreira V; Jiang M; Koch SE; Kelley M; Rubinstein J; Jones WK; Tranter M
Cardiovasc Pathol; 2014; 23(6):327-34. PubMed ID: 25035060
[TBL] [Abstract][Full Text] [Related]
33. Reduced cardiac remodeling and function in cardiac-specific EP4 receptor knockout mice with myocardial infarction.
Qian JY; Harding P; Liu Y; Shesely E; Yang XP; LaPointe MC
Hypertension; 2008 Feb; 51(2):560-6. PubMed ID: 18180401
[TBL] [Abstract][Full Text] [Related]
34. FT011, a new anti-fibrotic drug, attenuates fibrosis and chronic heart failure in experimental diabetic cardiomyopathy.
Zhang Y; Edgley AJ; Cox AJ; Powell AK; Wang B; Kompa AR; Stapleton DI; Zammit SC; Williams SJ; Krum H; Gilbert RE; Kelly DJ
Eur J Heart Fail; 2012 May; 14(5):549-62. PubMed ID: 22417655
[TBL] [Abstract][Full Text] [Related]
35. Connective tissue growth factor inhibition attenuates left ventricular remodeling and dysfunction in pressure overload-induced heart failure.
Szabó Z; Magga J; Alakoski T; Ulvila J; Piuhola J; Vainio L; Kivirikko KI; Vuolteenaho O; Ruskoaho H; Lipson KE; Signore P; Kerkelä R
Hypertension; 2014 Jun; 63(6):1235-40. PubMed ID: 24688123
[TBL] [Abstract][Full Text] [Related]
36. Cardiomyocyte-specific overexpression of oestrogen receptor β improves survival and cardiac function after myocardial infarction in female and male mice.
Schuster I; Mahmoodzadeh S; Dworatzek E; Jaisser F; Messaoudi S; Morano I; Regitz-Zagrosek V
Clin Sci (Lond); 2016 Mar; 130(5):365-76. PubMed ID: 26608078
[TBL] [Abstract][Full Text] [Related]
37. Inhibiting Fibronectin Attenuates Fibrosis and Improves Cardiac Function in a Model of Heart Failure.
Valiente-Alandi I; Potter SJ; Salvador AM; Schafer AE; Schips T; Carrillo-Salinas F; Gibson AM; Nieman ML; Perkins C; Sargent MA; Huo J; Lorenz JN; DeFalco T; Molkentin JD; Alcaide P; Blaxall BC
Circulation; 2018 Sep; 138(12):1236-1252. PubMed ID: 29653926
[TBL] [Abstract][Full Text] [Related]
38. The H19 long noncoding RNA is a novel negative regulator of cardiomyocyte hypertrophy.
Liu L; An X; Li Z; Song Y; Li L; Zuo S; Liu N; Yang G; Wang H; Cheng X; Zhang Y; Yang X; Wang J
Cardiovasc Res; 2016 Jul; 111(1):56-65. PubMed ID: 27084844
[TBL] [Abstract][Full Text] [Related]
39. Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction.
Mohammed SF; Hussain S; Mirzoyev SA; Edwards WD; Maleszewski JJ; Redfield MM
Circulation; 2015 Feb; 131(6):550-9. PubMed ID: 25552356
[TBL] [Abstract][Full Text] [Related]
40. The alteration of protein prenylation induces cardiomyocyte hypertrophy through Rheb-mTORC1 signalling and leads to chronic heart failure.
Xu N; Guan S; Chen Z; Yu Y; Xie J; Pan FY; Zhao NW; Liu L; Yang ZZ; Gao X; Xu B; Li CJ
J Pathol; 2015 Apr; 235(5):672-85. PubMed ID: 25385233
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
